Cited by 7Malaria Research and ControlBlood groups and transfusionPregnancy and preeclampsia studies

A conserved epitope in VAR2CSA is targeted by a cross-reactive antibody originating from Plasmodium vivax Duffy binding protein

Open access
Iyamu, Uwa, Vinals, Daniel Ferrer, Tornyigah, Bernard, Arango, Eliana, Bhat, Rakesh, Adra, Trixie Rae, Grewal, Simranjit, Martin, Kimberly +4 more·2023·Frontiers in Cellular and Infection Microbiology

Abstract

During Plasmodium falciparum infection in pregnancy, VAR2CSA is expressed on the surface of infected erythrocytes (IEs) and mediates their sequestration in the placenta. As a result, antibodies to VAR2CSA are largely restricted to women who were infected during pregnancy. However, we discovered that VAR2CSA antibodies can also be elicited by P. vivax Duffy binding protein (PvDBP). We proposed that infection with P. vivax in non-pregnant individuals can generate antibodies that cross-react with VAR2CSA. To better understand the specificity of these antibodies, we took advantage of a mouse monoclonal antibody (3D10) raised against PvDBP that cross-reacts with VAR2CSA and identified the epitopes targeted by this antibody. We screened two peptide arrays that span the ectodomain of VAR2CSA from the FCR3 and NF54 alleles. Based on the top epitope recognized by 3D10, we designed a 34-amino acid synthetic peptide, which we call CRP1, that maps to a highly conserved region in DBL3X. Specific lysine residues are critical for 3D10 recognition, and these same amino acids are within a previously defined chondroitin sulfate A (CSA) binding site in DBL3X. We showed by isothermal titration calorimetry that the CRP1 peptide can bind directly to CSA, and antibodies to CRP1 raised in rats significantly blocked the binding of IEs to CSA in vitro. In our Colombian cohorts of pregnant and non-pregnant individuals, at least 45% were seroreactive to CRP1. Antibody reactivities to CRP1 and the 3D10 natural epitope in PvDBP region II, subdomain 1 (SD1), were strongly correlated in both cohorts. These findings suggest that antibodies arising from PvDBP may cross-react with VAR2CSA through the epitope in CRP1 and that CRP1 could be a potential vaccine candidate to target a distinct CSA binding site in VAR2CSA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fcimb.2023.1202276

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Iyamu et al. (2023) demonstrated that the VAR2CSA protein is expressed on the surface of erythrocytes infected with P.vivax and facilitates their sequestration within the placenta.

    “In contrast, Iyamu et al. (2023) demonstrated that the VAR2CSA protein is expressed on the surface of erythrocytes infected with P.vivax and facilitates their sequestration within the placenta.”

    From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as Iyamu et al. (2023)

    The Introduction attributes placental sequestration through VAR2CSA to P. falciparum-infected erythrocytes, not P. vivax-infected erythrocytes. The paper discusses P. vivax Duffy binding protein as a source of antibodies that cross-react with VAR2CSA; it does not say P. vivax expresses VAR2CSA on infected erythrocytes. (LLM, conf=0.90)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Antibodies targeting VAR2CSA have been primarily associated with infections during pregnancy, and antibodies directed against the P.vivax Duffy Binding Protein (PvDBP) were found to cross-react with VAR2CSA due to the presence of an epitope in the CRP1 domain, suggesting that CRP1 is a potential vaccine candidate that could target a specific CSA binding site within VAR2CSA.

    “Antibodies targeting VAR2CSA have been primarily associated with infections during pregnancy, and antibodies directed against the P.vivax Duffy Binding Protein (PvDBP) were found to cross-react with VAR2CSA due to the presence of an epitope in the CRP1 domain, suggesting that CRP1 is a potential vaccine candidate that could target a specific CSA binding site within VAR2CSA [113].”

    From Current update on malaria in pregnancy: a systematic review (2025) · cites this paper as [113]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Iyamu, U., Vinals, D. F., Tornyigah, B., Arango, E., Bhat, R., Adra, T. R., Grewal, S., Martin, K., Maestre, A., Overduin, M., Hazes, B., & Yanow, S. K.
Affiliations
  • University of Alberta (CA)
  • Fundación Universitaria San Martín (CO)
  • Universidad de Antioquia (CO)
Corresponding author
Yanow, Stephanie K.
Venue
Frontiers in Cellular and Infection Microbiology
Published
2023-06-16
Volume
13
Pages
1202276-1202276
ISSN
2235-2988 (ISSN-L)
OpenAlex
W4380992446
Cited by
7
References
59
Citations by year
2026: 1 · 2025: 3 · 2024: 3
FWCI
1.79
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Cellular and Infection Microbiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Greater South Information System
Funders
  • National Institute of Allergy and Infectious Diseases
  • Li Ka Shing Institute of Virology, University of Alberta
  • Canadian Institutes of Health Research
  • Canada Foundation for Innovation
  • Natural Sciences and Engineering Research Council of Canada
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Health Sciences › Medicine › Hematology › Blood groups and transfusion
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Keywords
VAR2CSA, cross-reactive antibodies, conserved epitopes, placental sequestration, malaria in pregnancy, Plasmodium falciparum, vaccine candidate, epitope mapping
MeSH terms
Animals, Antibodies, Protozoan, Epitopes, Antigens, Protozoan, Chondroitin Sulfates, Erythrocytes, Female, Placenta, Plasmodium falciparum, Plasmodium vivax, Pregnancy, Protein Binding, Malaria, Falciparum, Malaria, Vivax, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review